Cassava Sciences Announces Expansion Of Open-Label Extension Trials By Up To An Additional 36 Months To Provide Participants The Opportunity To Continue On Treatment, If They Desire, Pending Results Of The Ongoing Phase 3 Trials

Author: Benzinga Newsdesk | July 30, 2024 08:19am

• Ongoing open-label extension trials of simufilam in Alzheimer's disease to be extended by up to an additional 36 months.
• The extension provides participants the opportunity to continue on treatment, if they desire, pending results of the ongoing pivotal Phase 3 trials.
• Company plans to add cognition and plasma biomarker monitoring to the open-label extension trials to gather additional long-term data on simufilam treatment.

AUSTIN, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Company will extend by up to an additional 36 months each of the open-label extension trials in its ongoing Phase 2 and Phase 3 clinical programs. These amendments to the protocols will allow patients who have previously participated in a randomized trial of simufilam in Alzheimer's disease, if they desire, to continue open-label treatment with simufilam. This expansion of the open-label extension trials offers a bridge for any gap between patients ending treatment in a clinical trial and the Company reporting to regulatory authorities the results of the ongoing, randomized, placebo-controlled Phase 3 trials. The open-label extension can continue for up to 36 months or until a new drug application for simufilam has been reviewed by FDA.

Posted In: SAVA